M
Mario Masellis
Researcher at Sunnybrook Health Sciences Centre
Publications - 290
Citations - 9815
Mario Masellis is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Frontotemporal dementia & Medicine. The author has an hindex of 42, co-authored 212 publications receiving 6662 citations. Previous affiliations of Mario Masellis include Sunnybrook Research Institute & Centre for Addiction and Mental Health.
Papers
More filters
Journal ArticleDOI
Quality of life in OCD: differential impact of obsessions, compulsions, and depression comorbidity.
TL;DR: Obsession severity was found to significantly predict patient QOL, whereas the severity of compulsive rituals did not impact on QOL ratings, and treatments that directly target obsessions and secondary depression symptoms in OCD are warranted.
Journal ArticleDOI
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Stephen Salloway,Martin R. Farlow,Eric McDade,David B. Clifford,Guoqiao Wang,Jorge J. Llibre-Guerra,Janice M. Hitchcock,Susan Mills,Anna Santacruz,Andrew J. Aschenbrenner,Jason Hassenstab,Tammie L.S. Benzinger,Brian A. Gordon,Anne M. Fagan,Kelley Coalier,Carlos Cruchaga,Alison Goate,Richard J. Perrin,Chengjie Xiong,Yan Li,John C. Morris,B. Joy Snider,Catherine J. Mummery,G. Mustafa Surti,Didier Hannequin,David Wallon,Sarah B. Berman,James J. Lah,Ivonne Z. Jimenez-Velazquez,Erik D. Roberson,Christopher H. van Dyck,Lawrence S. Honig,Raquel Sánchez-Valle,William S. Brooks,Serge Gauthier,Douglas Galasko,Colin L. Masters,Jared R. Brosch,Ging-Yuek Robin Hsiung,Suman Jayadev,Maïté Formaglio,Mario Masellis,Roger Clarnette,J. Pariente,Bruno Dubois,Florence Pasquier,Clifford R. Jack,Robert A. Koeppe,Peter J. Snyder,Paul S. Aisen,Ronald G. Thomas,Scott M. Berry,Barbara A. Wendelberger,Scott W. Andersen,Karen C. Holdridge,Mark A. Mintun,Roy Yaari,John R. Sims,Monika Baudler,Paul Delmar,Rachelle S. Doody,Paulo Fontoura,Caroline Giacobino,Geoffrey A. Kerchner,Randall J. Bateman +64 more
TL;DR: A randomized, placebo-controlled, multi-arm trial of gantenerumab or solanezumab in participants with DIAD across asymptomatic and symptomatic disease stages was conducted in this paper.
Journal ArticleDOI
Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders
Simon Ducharme,Annemiek Dols,Robert Laforce,Emma Devenney,Fiona Kumfor,Jan Van den Stock,Caroline Dallaire-Théroux,Harro Seelaar,Flora Gossink,Everard G. B. Vijverberg,Edward D. Huey,Mathieu Vandenbulcke,Mario Masellis,Calvin Trieu,Chiadi U. Onyike,Paulo Caramelli,Leonardo Cruz de Souza,Alexander Santillo,Maria Landqvist Waldö,Ramon Landin-Romero,Olivier Piguet,Wendy Kelso,Dhamidhu Eratne,Dennis Velakoulis,Manabu Ikeda,David C. Perry,Peter Pressman,Bradley F. Boeve,Rik Vandenberghe,Mario F. Mendez,Carole Azuar,Richard Levy,Isabelle Le Ber,Sandra Baez,Alan J. Lerner,Ratnavalli Ellajosyula,Florence Pasquier,Daniela Galimberti,Elio Scarpini,John C. van Swieten,Michael Hornberger,Howard J. Rosen,John R. Hodges,Janine Diehl-Schmid,Yolande A.L. Pijnenburg +44 more
TL;DR: The goal of the present paper was to review the existing literature on the diagnosis of bvFTD and its differential diagnosis with primary psychiatric disorders to provide consensus recommendations on the clinical assessment and clarify the role of 18F-fluorodeoxyglucose PET for the exclusion of b vFTD.
Journal ArticleDOI
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
Sidney H. Kennedy,Sonia McCann,Mario Masellis,Roger S. McIntyre,Joel Raskin,Gordon McKay,Glen B. Baker +6 more
TL;DR: Bupropion had an effect on the pharmacokinetics of venlafaxine but not those of the SSRIs.
Journal ArticleDOI
Pharmacogenomics in schizophrenia: the quest for individualized therapy
TL;DR: This review will provide demonstrative examples of functional candidate gene variants studied in a variety of antipsychotic response phenotypes in the treatment of schizophrenia, and the merits and weaknesses of neuroimaging technologies as applied to pharmacogenetic analyses are discussed.